In Reply We thank Bonadies et al for their insightful commentary on our article.1 The authors make a valid argument on the possibility of using postnatal corticosteroids (PNCs) in preterm neonates who are treated with noninvasive respiratory support (NRS). We agree that our analysis did not look at this specific group of neonates who were supported with NRS at the time of randomization. This was because of the paucity of available studies.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ramaswamy VV, Roehr CC. Is a New Era Coming for Bronchopulmonary Dysplasia Prevention With Corticosteroids?—Reply. JAMA Pediatr. 2021;175(10):1079–1080. doi:10.1001/jamapediatrics.2021.1861
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.